Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors

Longjia Yan, Qin Wang, Li Liu & Yi Le
This paper described our efforts to develop dianilinopyrimidines as novel EGFR inhibitors. All the target compounds were tested for inhibitory effects against wild type EGFR (EGFRwt) and three tumour cells, including A549, PC-3, and HepG2. Some of the compounds performed well in antitumor activities. Especially, compound 4c 2-((2-((4-(3-fluorobenzamido)phenyl)amino)-5-(trifluoromethyl) pyrimidin-4-yl)amino)-N-methylthiophene-3-carboxamide showed higher anti-tumour activities than Gefitinib. The IC50 values of compound 4c against A549, PC-3, and HepG2. reached 0.56 μM, 2.46 μM, and 2.21 μM, respectively....
1 citation reported since publication in 2022.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.